Chromium effects on glucose tolerance and insulin sensitivity in persons at risk for diabetes mellitus.
Chromium effects on glucose tolerance and insulin sensitivity in persons at risk for diabetes mellitus.
复制标题
DOI：
10.4158/ep10131.or
复制
发表时间：
2011-01
期刊：
影响因子：
--
通讯作者：
Katz DL
中科院分区：
文献类型：
--
作者：
Ali A;Ma Y;Reynolds J;Wise JP Sr;Inzucchi SE;Katz DL
目的 研究每日补充吡啶甲酸铬对 2 型糖尿病高危患者血清葡萄糖耐量和胰岛素敏感性的影响。我们进行了一项随机、双盲、安慰剂对照、改良交叉临床试验，采用为期 6 个月的干预和安慰剂序列，随后进行 6 个月的干预后评估。患有空腹血糖受损、糖耐量受损或代谢综合征的成年患者被纳入研究。参与者接受为期 6 个月的吡啶甲酸铬或安慰剂序列，分 2 剂中的 1 剂（每天 500 或 1000 微克）。主要结果指标是空腹血糖、口服葡萄糖耐量试验期间2小时血糖的变化、空腹和2小时胰岛素以及胰岛素抵抗的稳态模型评估（HOMA-IR）。次要结果包括人体测量、血压、内皮功能、糖化血红蛋白、血脂和尿微量白蛋白。共有五十九名参与者参加。与安慰剂相比，服用任一剂量水平（每日 500 微克或 1000 微克）铬 6 个月后，血糖水平、胰岛素水平或 HOMA-IR 均未见变化（全部，P>.05）。与安慰剂相比，任何一种铬剂量的次要结果均未改善（P>.05）。补充铬似乎并不能改善有 2 型糖尿病风险的患者的胰岛素抵抗或葡萄糖代谢受损，因此不太可能降低糖尿病风险。
To investigate the effects of daily chromium picolinate supplementation on serum measures of glucose tolerance and insulin sensitivity in patients at high risk for type 2 diabetes mellitus. We conducted a randomized, double-blind, placebo-controlled, modified cross-over clinical trial with 6-month sequences of intervention and placebo followed by a 6-month postintervention assessment. Adult patients with impaired fasting glucose, impaired glucose tolerance, or metabolic syndrome were enrolled. Participants received 6-month sequences of chromium picolinate or placebo at 1 of 2 dosages (500 or 1000 mcg daily). Primary outcome measures were change in fasting plasma glucose, 2-hour plasma glucose during oral glucose tolerance testing, fasting and 2-hour insulin, and homeostasis model assessment of insulin resistance (HOMA-IR). Secondary outcomes included anthropometric measures, blood pressure, endothelial function, hemoglobin A1c, lipids, and urinary microalbumin. Fifty-nine participants were enrolled. No changes were seen in glucose level, insulin level, or HOMA-IR (all, P>.05) after 6 months of chromium at either dosage level (500 mcg or 1000 mcg daily) when compared with placebo. None of the secondary outcomes improved with either chromium dosage compared with placebo (P>.05). Chromium supplementation does not appear to ameliorate insulin resistance or impaired glucose metabolism in patients at risk for type 2 diabetes and thus is unlikely to attenuate diabetes risk.